Japan evaluates combination medical products—those integrating drugs, devices, or biologics—based on their primary mode of action. MHLW determines regulatory pathways & reimbursement classification, with Chuikyo assessing clinical benefits, safety, & cost-effectiveness. Reimbursement aligns with the National Health Insurance (NHI) system, often requiring robust evidence for both components to justify pricing.
